CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare CASI Pharmaceuticals to similar companies based on the strength of its dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.
Analyst Recommendations
This is a summary of current ratings and target prices for CASI Pharmaceuticals and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CASI Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| CASI Pharmaceuticals Competitors | 7819 | 13779 | 25777 | 1035 | 2.41 |
As a group, “Pharmaceuticals” companies have a potential upside of 24.02%. Given CASI Pharmaceuticals’ competitors stronger consensus rating and higher possible upside, analysts plainly believe CASI Pharmaceuticals has less favorable growth aspects than its competitors.
Risk and Volatility
CASI Pharmaceuticals has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, CASI Pharmaceuticals’ competitors have a beta of -0.05, suggesting that their average share price is 105% less volatile than the S&P 500.
Profitability
This table compares CASI Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CASI Pharmaceuticals | -183.93% | N/A | -131.54% |
| CASI Pharmaceuticals Competitors | -2,393.16% | -220.83% | -16.11% |
Institutional & Insider Ownership
22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares CASI Pharmaceuticals and its competitors revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| CASI Pharmaceuticals | $26.85 million | -$39.26 million | -0.07 |
| CASI Pharmaceuticals Competitors | $5.36 billion | $3.23 billion | 555.02 |
CASI Pharmaceuticals’ competitors have higher revenue and earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Summary
CASI Pharmaceuticals competitors beat CASI Pharmaceuticals on 9 of the 13 factors compared.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines, particularly for cancer and blood disorders. Its commercial and development activities have been centered largely on China. The company’s portfolio has included EVOMELA, a formulation of melphalan used in conditioning treatment for certain patients with multiple myeloma undergoing stem-cell transplantation. CASI has also pursued development and commercialization rights for additional oncology therapies, including CNCT19, an investigational CD19-directed CAR T-cell therapy.
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
